Agreements reached under this partnership
- 1
Create synergies with the biophysical analysis approach incorporating the concepts of AI-driven computational chemistry and quantum computing promoted by the company, and accelerate progress from target validation and exploratory research through clinical development using highly differentiated and optimized drug candidates
- 2
Ongoing use and evaluation of cutting-edge open-source structure prediction models, including OpenFold and OpenFold3-preview
- 3
Performance benchmarking focused on GPCR targets by the computational chemistry team
- 4
Participation in future research and development priorities through the governing council, and access to technical support
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
There will be no impact on consolidated results for the fiscal year ending December 2026, but we believe this transaction will contribute to growth in our business revenue and corporate value over the medium to long term.
| Item | Details |
|---|---|
| Name of alliance partner | OpenFold AI Research Consortium（OpenFold） |
| Alliance partner's business activities | A nonprofit AI Research Consortium promoting the development of open-source AI software tools for biology and drug discovery |
| Details of the alliance | Create synergies with the biophysical analysis approach incorporating the concepts of AI-driven computational chemistry and quantum computing promoted by the company, and accelerate progress from target validation and exploratory research through clinical development using highly differentiated and optimized drug candidates, Ongoing use and evaluation of cutting-edge open-source structure prediction models, including OpenFold and OpenFold3-preview, Performance benchmarking focused on GPCR targets by the computational chemistry team, Participation in future research and development priorities through the governing council, and access to technical support |
| Alliance start date | 10 June 2026 (joined today) |
| Impact on Business Performance | There will be no impact on consolidated results for the fiscal year ending December 2026, but we believe this transaction will contribute to growth in our business revenue and corporate value over the medium to long term. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The participation is in line with the company’s policy of improving R&D productivity and operating efficiency, centered on the use of AI technology. It will also strengthen the AI-driven drug discovery capabilities of the NxWave platform and enhance the company’s drug discovery capabilities for GPCRs.